GHK-Cu vs Growth Hormone

GHK-Cu and Growth Hormone are both studied across multiple research domains, yet they diverge sharply in mechanism, evidence level, and dosing protocols. GHK-Cu is a small, naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) that binds copper, primarily investigated for wound healing, skin regeneration, and gene modulation. Growth Hormone, a 191-amino acid protein hormone, is one of the most extensively studied hormones in medicine, with FDA approval for growth hormone deficiency and related disorders. This comparison highlights their unique research niches and helps clarify which peptide aligns with specific experimental goals.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu. Key research claims include improving skin firmness and elasticity, promoting wound healing, and reducing fine lines and wrinkles.

Human growth hormone (hGH, somatotropin) is a 191-amino acid protein produced by the anterior pituitary gland. It is one of the most extensively studied hormones in medicine. Key research claims include treating growth hormone deficiency in children and adults, and anti-aging effects.

These peptides target different research areas. GHK-Cu focuses on skin health, anti-aging, and wound healing, while Growth Hormone targets GH deficiency treatment and pediatric growth disorders. There is minimal overlap in their primary research applications, though both have been explored in the context of aging. GHK-Cu's effects are largely local and topical, whereas Growth Hormone exerts systemic metabolic and growth-promoting actions. Researchers should align their choice with the specific biological process under investigation.

GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520). Topical forms are generally well-tolerated; mild skin irritation is rare and typically limited to very sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating injection sites reduces local irritation. Growth Hormone: Common side effects include injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, and muscle pain (myalgia). Metabolic effects include glucose intolerance and insulin resistance (dose-dependent), with potential progression to type 2 diabetes. Fluid retention, especially peripheral edema, often occurs at treatment initiation.